AT

ATUM CO., LTD.

An integrated biologics development partner offering services from DNA sequence to cell bank.

355690 | KO

Overview

Corporate Details

ISIN(s):
KR7355690009
LEI:
Country:
South Korea
Address:
서울특별시 구로구 디지털로31길 38-9 에이스테크노타워1차 6층 603-2호, 구로구

Description

ATUM is an integrated biologics development partner offering a comprehensive suite of services, from virtual DNA sequence to research cell bank. The company's core activities include gene design and synthesis, protein expression and analytics, cell line development, and antibody and protein engineering. Utilizing expertise in machine learning and proprietary platforms like DNA2GO for gene fragments and the lightningHEK and discoCHO expression systems, ATUM facilitates the discovery and optimization processes for its clients. The company operates as a collaborative, one-stop partner for biological engineering projects, providing fully in-house services.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-12-31 00:00
유상증자결정(종속회사의주요경영사항)
Korean HTML 24.8 KB
2025-12-31 00:00
타법인주식및출자증권취득결정
Korean HTML 26.3 KB
2025-12-23 00:00
[정정제출요구]증권신고서(지분증권)
Korean HTML 2.7 MB
2025-12-23 00:00
주요사항보고서(유상증자결정)
Korean HTML 32.9 KB
2025-08-14 00:00
반기보고서 (2025.06)
Korean HTML 1.6 MB
2025-07-29 00:00
타인에대한채무보증결정
Korean HTML 10.4 KB
2025-05-15 00:00
분기보고서 (2025.03)
Korean HTML 1.8 MB
2025-05-07 00:00
합병등종료보고서(자산양수도)
Korean HTML 15.1 KB
2025-05-02 00:00
단기차입금증가결정
Korean HTML 9.4 KB
2025-04-29 00:00
주요사항보고서(전환사채권발행결정)
Korean HTML 65.7 KB
2025-04-29 00:00
[기재정정]주요사항보고서(타법인주식및출자증권양수결정)
Korean HTML 57.6 KB
2025-04-29 00:00
[기재정정]주요사항보고서(전환사채권발행결정)
Korean HTML 70.0 KB
2025-04-29 00:00
증권발행결과(자율공시) (제4회차 CB)
Korean HTML 6.0 KB
2025-04-02 00:00
합병등종료보고서(자산양수도)
Korean HTML 14.9 KB
2025-04-01 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 24.4 KB

Automate Your Workflow. Get a real-time feed of all ATUM CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ATUM CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ATUM CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.